Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 1
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer.
Kawai T, Taguchi S, Nozaki K, Kimura N, Oshina T, Iwaki T, Matsui H, Niimi A, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Kaneko T, Sawayanagi S, Nakayama H, Minamimoto R, Yamashita H, Miyazaki H, Fujimura T, Nakagawa T, Kume H. Kawai T, et al. Among authors: sawayanagi s. Prostate Int. 2023 Dec;11(4):239-246. doi: 10.1016/j.prnil.2023.10.002. Epub 2023 Oct 21. Prostate Int. 2023. PMID: 38196558 Free PMC article.
Retrospective comparison between definitive stereotactic body radiotherapy and radical surgery for 538 patients with early-stage non-small cell lung cancer in a single institution.
Miki Y, Yamashita H, Nakajima J, Karasaki T, Kitano K, Katano A, Takenaka R, Ogita M, Sawayanagi S, Minamitani M, Jinnouchi H, Noyama T, Takeuchi K, Ishida A, Abe O. Miki Y, et al. Among authors: sawayanagi s. J Cancer Res Ther. 2023 Jul-Sep;19(5):1350-1355. doi: 10.4103/jcrt.jcrt_1873_21. J Cancer Res Ther. 2023. PMID: 37787307 Free article.
Relationship between hydrogel spacer distribution and dosimetric parameters in linear-accelerator-based stereotactic body radiotherapy for prostate cancer.
Ohira S, Yamashita H, Minamitani M, Sawayanagi S, Ogita M, Imae T, Katano A, Nozawa Y, Ohta T, Nawa K, Nishio T, Koizumi M, Nakagawa K. Ohira S, et al. Among authors: sawayanagi s. J Appl Clin Med Phys. 2024 Feb 6:e14294. doi: 10.1002/acm2.14294. Online ahead of print. J Appl Clin Med Phys. 2024. PMID: 38319652
11 results